SecurityHGH / Hartford Financial Services Group, 7.875% Fixed/Float, Jr Sub Debentures 4/15/42 (416518504)
Chairman and CEOSwift Christopher
IndustryFire, Marine, and Casualty Insurance
Institutional Owners4
Institutional Shares242,026 - 0.07%
Common Shares Outstanding358,419,118 shares (as of 2018-06-30)
Institutional Value$ 7,043,000 USD
Related 416515AU8 / Hartford Financial Services 6.3% Senior Notes 3/15/18
416515AP9 / Hartford Financial Services Group6.1% 10/1/2041
HIG.WS / Hartford Financial Services Group, Inc. (The)
HIG / Hartford Financial Services Group, Inc. (The)
416515AW4 / Hartford Financial Svcs Grp 8.125% Jr Sub 06/15/38
416515AY0 / Hartford Finl Svcs Group Inc Senior Notes 4% 03/30/15
416515AT1 / Hartford Finl Svcs Group Inc Senior Notes 5.375% 03/15/17
416515AZ7 / Hartford Finl Svcs Group Inc Senior Notes 5.5% 03/30/20
416515AV6 / Hartford Finl Svcs Group Inc Senior Notes 6% 01/15/19
416515BA1 / Hartford Finl Svcs Group Inc Senior Notes 6.625% 03/30/40
416518AA6 / Hartford Finl Svcs Grp 4.0% Senior Notes 10/15/17
416518AB4 / Hartford Finl Svcs Grp 5.125% Senior Notes 04/15/22
416518AC2 / Hartford Finl Svcs Grp 6.625% Senior Notes 04/15/42
416592AC7 / Hartford Life Inc 7.650% Debentures 06/15/27
416592AE3 / Hartford Life Inc Senior Notes 7.375% 03/01/31
45068HAF3 / Itt Hartford Group 7.30% Debentures 11/01/2015
416515AL8 / The Hartford Finl Svcs Gr 4.625% Notes 07/15/13
416515AM6 / The Hartford Finl Svcs Gr 4.750% Sr 03/01/14
416515AR5 / The Hartford Finl Svcs Gr 5.5% 10/15/16
416515AS3 / The Hartford Finl Svcs Gr 5.95% 10/15/36

Institutional Bond Ownership and Shareholders

HGH / Hartford Financial Services Group, 7.875% Fixed/Float, Jr Sub Debentures 4/15/42 Institutional Ownership

Hartford Financial Services Group, 7.875% Fixed/Float, Jr Sub Debentures 4/15/42 (NYSE:HGH) has 4 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 242,026 shares. Largest shareholders include Roosevelt Investment Group Inc, Kcm Investment Advisors Llc, Sonora Investment Management, LLC, and Glenmede Trust Co Na.
Hartford Financial Services Group, 7.875% Fixed/Float, Jr Sub Debentures 4/15/42 (NYSE:HGH) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-08-09 13F-HR ROOSEVELT INVESTMENT GROUP INC 184,960 202,710 9.60 5,429 5,899 8.66
2018-08-13 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 17,177 0 -100.00 504 0 -100.00
2018-08-15 13F-HR GLENMEDE TRUST CO NA 12 0
2018-08-06 13F-HR Sonora Investment Management, LLC 104 104 0.00 3,052 3 -99.90
2018-08-10 13F-HR KCM INVESTMENT ADVISORS LLC 40,240 39,200 -2.58 1,181 1,141 -3.39

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Focus on These 3 Hartford Mutual Funds for Strong Gains

22h zacks
Hartford Funds, a segment of The Hartford Financial Services Group, Inc. (HIG - Free Report) , has total assets of around $117 billion under management (as of Jun 30, 2018). The company claims to manage at least 55 mutual funds across a wide range of styles and asset classes. Hartford Financial Services was founded in 1810 and is a well-recognized insurance company in the United States. (6-0)

Will Hurricane Florence Rattle Property & Casualty Insurers?

2018-09-12 zacks
After being blessed by a quieter catastrophe period, the second half of the year seems to be a different one for the insurers, with Hurricane Florence nearing Carolina coast as a Category 4 storm. (8-0)

3 Big Stock Charts for Thursday: Kroger, Prologis and Hartford Financial Services Group

2018-09-06 investorplace
Although it got close a couple of times, the S&P 500 never tiptoed into the black on Wednesday. Neither did the Nasdaq. The blue-chip-heavy Dow Jones Industrial Average did, however. In fact, the Dow closed up to the tune of 0.09%. It’s not an earth-shattering victory, but it does suggest that investors are starting to look for safe-haven stocks. Dow names would be a good place to start. (33-1)

Insurer Great-West Lifeco seeks to sell $2 bln worth of contracts- sources

2018-09-05 reuters
(Reuters) - Great-West Lifeco Inc (GWO.TO), Canada’s second-biggest insurance company, is exploring the sale of a collection of insurance contacts that could fetch as much as $2 billion, three people familiar with the matter said on Wednesday. (10-0)

Aspen Insurance to Get Acquired by Apollo Global for $2.6B

2018-08-28 zacks
Aspen Insurance Holdings Limited (AHL - Free Report) has agreed to be acquired by certain investment funds affiliated with Apollo Global Management LLC (APO - Free Report) for $2.6 billion in cash. The deal is expected to culminate in the first half of 2019, subject to closing conditions. The buyout agreement follows a strategic analysis by Aspen’s board of directors to provide its shareholders with immediate value. (8-0)

CUSIP: 416518504